- Home
- PLTR vs NVS Comparison
PLTR vs NVS Comparison
Compare PLTR & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLTR
- NVS
- Stock Information
- Founded
- PLTR 2003
- NVS 1895
- Country
- PLTR United States
- NVS Switzerland
- Employees
- PLTR N/A
- NVS N/A
- Industry
- PLTR Retail: Computer Software & Peripheral Equipment
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- PLTR Technology
- NVS Health Care
- Exchange
- PLTR Nasdaq
- NVS Nasdaq
- Market Cap
- PLTR 207.7B
- NVS 230.5B
- IPO Year
- PLTR 2020
- NVS 1991
- Fundamental
- Price
- PLTR $93.18
- NVS $110.20
- Analyst Decision
- PLTR Hold
- NVS Hold
- Analyst Count
- PLTR 21
- NVS 6
- Target Price
- PLTR $78.79
- NVS $123.67
- AVG Volume (30 Days)
- PLTR 112.5M
- NVS 2.9M
- Earning Date
- PLTR 05-05-2025
- NVS 04-29-2025
- Dividend Yield
- PLTR N/A
- NVS 2.99%
- EPS Growth
- PLTR 111.11
- NVS N/A
- EPS
- PLTR 0.19
- NVS 5.87
- Revenue
- PLTR $2,865,507,000.00
- NVS $51,722,000,000.00
- Revenue This Year
- PLTR $34.25
- NVS $4.36
- Revenue Next Year
- PLTR $28.46
- NVS $1.93
- P/E Ratio
- PLTR $487.95
- NVS $18.67
- Revenue Growth
- PLTR 28.79
- NVS 10.85
- 52 Week Low
- PLTR $20.33
- NVS $92.35
- 52 Week High
- PLTR $125.41
- NVS $120.92
- Technical
- Relative Strength Index (RSI)
- PLTR 55.51
- NVS 53.97
- Support Level
- PLTR $89.62
- NVS $109.22
- Resistance Level
- PLTR $98.99
- NVS $110.76
- Average True Range (ATR)
- PLTR 7.45
- NVS 2.87
- MACD
- PLTR 1.41
- NVS 0.25
- Stochastic Oscillator
- PLTR 86.07
- NVS 74.82
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.